On Sept. 25, 2026, the US Food and Drug Administration announced approval of AbbVie’s treatment for Parkinson’s ​disease in adults, the health regulator’s website showed ‌on Friday.

The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes ​as a once-a-day pill.

Parkinson’s is a long-term brain condition that ​gradually damages movement control, often causing tremors, stiffness ​and balance issues. More than 11 million people live with the disease worldwide, according to AbbVie.

Juvmo works by mimicking dopamine, ​a vital brain chemical that naturally decreases in ​people with Parkinson’s.

The regulator’s nod was based on data from AbbVie’s ‌late-stage ⁠trial program which showed the drug improved symptoms in patients with the disease. Common side effects reported in the trials included nausea, dizziness and headache.